The federal Drug Enforcement Administration "prescription series" proposal: continuing concerns.
Two leading health and pain policy analysts discuss the implications of the federal Drug Enforcement Administration proposed position on the legality of practitioners writing series of controlled substance prescriptions for the purpose of providing ongoing pain management without the necessity for unneeded patient visits to their prescribers. This issue led to a series of regulatory proposals that engendered great concern in the pain management community. The proposed positive outcome from the DEA is described.
Gilson
Aaron M
AM
U.S. Policy Research, World Health Organization Collaborationg Center for Policy and Communications in Cancer Care, University of Wisconsin-Madison, 406 Science Drive, Suite 202, Madison, WI 53711-1068, USA. amgilson@wisc.edu
Joranson
David E
DE
D000701:Analgesics, Opioid / Q000627:therapeutic use; D011307:Drug Prescriptions; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006077:Government Agencies; D006801:Humans; D010146:Pain / Q000188:drug therapy; D014481:United States
D000701:Analgesics, Opioid